文献速递临床试验与 GCP基础与转化研究

节拍化疗联合抗PD-1治疗转移性乳腺癌:一项贝叶斯适应性随机2期试验

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.
PubMed 文献 · Nat Med · 2024-07-05

该2期试验采用贝叶斯适应性随机化与疗效监测,在97例转移性HER2阴性乳腺癌患者中比较5种方案的疾病控制率(DCR)与安全性。VEX队列(节拍环磷酰胺、卡培他滨、长春瑞滨联合特瑞普利单抗)DCR为69.7%,顺铂队列为73.7%,VEX队列中位无进展生存期最长,达6.6个月。

要点

  • VEX队列DCR为69.7%,顺铂队列为73.7%,为各队列中最高。
  • VEX队列中位PFS最长,达6.6个月,贝伐珠单抗队列为4.0个月,顺铂队列为3.5个月。
  • 五种方案总体耐受良好,恶心与中性粒细胞减少为最常见不良事件。

核心结论

  • 节拍VEX化疗联合PD-1阻断可作为乳腺癌患者的一种治疗选择。

研究设计与样本

  • 一项采用贝叶斯适应性随机化与疗效监测的2期临床试验,共纳入97例转移性HER2阴性乳腺癌患者,且既往接受标准化疗不超过一线。
  • 患者随机分配至5个队列:节拍长春瑞滨单药(n=11)、长春瑞滨联合抗PD-1特瑞普利单抗(n=7)、抗血管生成贝伐珠单抗联合长春瑞滨及特瑞普利单抗(n=27)、常规顺铂联合长春瑞滨及特瑞普利单抗(n=26)、节拍环磷酰胺联合卡培他滨、长春瑞滨及特瑞普利单抗(VEX队列)(n=26)。
  • 主要终点为疾病控制率(DCR),次要目标包括无进展生存期(PFS)与安全性。

主要发现

  • 研究达到主要终点,VEX队列DCR为69.7%,顺铂队列为73.7%,为各队列中最高。
  • VEX队列中位PFS最长,达6.6个月,贝伐珠单抗队列为4.0个月,顺铂队列为3.5个月。
  • 五种方案总体耐受良好,恶心与中性粒细胞减少为最常见不良事件。
  • 探索性质谱流式分析提示节拍VEX化疗可重编程全身免疫反应。

关键数值与推荐

  • VEX队列DCR为69.7%,顺铂队列DCR为73.7%。
  • VEX队列中位PFS为6.6个月,贝伐珠单抗队列为4.0个月,顺铂队列为3.5个月。

临床怎么用

  • 作者认为,节拍VEX化疗联合PD-1阻断可作为乳腺癌患者的一种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It remains unclear whether metronomic chemotherapy is superior to conventional chemotherapy when combined with immune checkpoint blockade. Here we performed a phase 2 clinical trial of metronomic chemotherapy combined with PD-1 blockade to compare the efficacy of combined conventional chemotherapy and PD-1 blockade using Bayesian adaptive randomization and efficacy monitoring. Eligible patients had metastatic HER2-negative breast cancer and had not received more than one prior line of standard chemotherapy. Patients (total n = 97) were randomized to receive (1) metronomic vinorelbine (NVB) monotherapy (n = 11), (2) NVB plus anti-PD-1 toripalimab (n = 7), (3) anti-angiogenic bevacizumab, NVB and toripalimab (n = 27), (4) conventional cisplatin, NVB and toripalimab (n = 26), or (5) metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n = 26). The primary endpoint was disease control rate (DCR). Secondary objectives included progression-free survival (PFS) and safety. The study met the primary endpoint. The VEX (69.7%) and cisplatin (73.7%) cohorts had the highest DCR. The median PFS of patients in the VEX cohort was the longest, reaching 6.6 months, followed by the bevacizumab (4.0 months) and cisplatin (3.5 months) cohorts. In general, the five regimens were well tolerated, with nausea and neutropenia being the most common adverse events. An exploratory mass cytometry analysis indicated that metronomic VEX chemotherapy reprograms the systemic immune response. Together, the clinical and translational data of this study indicate that metronomic VEX chemotherapy combined with PD-1 blockade can be a treatment option in patients with breast cancer. ClinicalTrials.gov Identifier: NCT04389073 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mo H, Yu Y, Sun X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024. PMID: 38969879. doi:10.1038/s41591-024-03088-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。